Static export generated 2026-07-31 07:45Z from the private Meridian research build — every value keeps its own as-of timestamp and provenance label; search, filters and admin actions are inactive in this copy. Private academic review only — not for redistribution.
MERIDIAN Regulatory & Corporate Impact Intelligence — personal research build

Regulatory instrument

Official record

Official Regulatory Fact — text as published by the source; topics are matching candidates, not legal conclusions.

FieldValue
Canonical identifierUS-BILL-119-HR9421
TitleHR 9421 (119th Congress): To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
Authorityus_congress
JurisdictionUS
Typebill
Legal stageproposal
Publication date2026-06-24
Discovered at2026-07-07T17:36:49Z
SR / CELEXn/a
Affected countries (parsed from title)none parsed
Matched topicsenergy_environment (energy)
Original sourcehttps://www.congress.gov/bill/119th-congress/house-bill/9421
Summary (as published)Referred to the House Committee on Energy and Commerce.
ⓘ